Novel cytochrome P450 bioactivation of a terminal phenyl acetylene group: Formation of a one-carbon loss benzaldehyde and other oxidative products in the presence of N -acetyl cysteine or glutathione

Chemical Research in Toxicology

Volumn 24, Issue 5, 2011, Pages 677-686

  Subramanian, Raju ^a   Tam, Janet ^a   Aidasani, Divesh ^a   Reid, Darren L ^a   Skiles, Gary L ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[N1 (3 ETHYNYLPHENYL) 6 METHYL N5 [3 [6 (METHYLAMINO)PYRIMIDIN 4 YL]PYRIDIN 2 YL]ISOQUINOLINE 1,5 DIAMINE]; ACETYLCYSTEINE; ACETYLENE DERIVATIVE; ASCORBIC ACID; BENZALDEHYDE; CARBON; CYTOCHROME P450; DEFEROXAMINE; ERLOTINIB; GLUTATHIONE; PHENYLACETIC ACID DERIVATIVE; PYRIMIDINE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ARTICLE; BIOTRANSFORMATION; CHEMICAL REACTION; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FENTON REACTION; MASS SPECTROMETRY; METABOLITE; MOLECULAR MECHANICS; NUCLEAR MAGNETIC RESONANCE; OXIDATION; RADIOACTIVITY; RADIOCHROMATOGRAPHY;

ACETYLCYSTEINE; ACETYLENE; ANIMALS; ANTIOXIDANTS; ASCORBIC ACID; BENZALDEHYDES; CATTLE; CHELATING AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DEFEROXAMINE; DOGS; GLUTATHIONE; HUMANS; MALE; OXIDATION-REDUCTION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79956149680     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx1004375     Document Type: Article

References (16)

1. Smith, A. L., DeMorin, F. F., Paras, N. A., Huang, Q., Petkus, J. K., Doherty, E. M., Nixey, T., Kim, J. L., Whittington, D. A., Epstein, L. F., Lee, M. R., Rose, M. J., Babij, C., Fernando, M., Hess, K., Le, Q., Beltran, P., and Carnahan, J. (2009) Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline J. Med. Chem. 52, 6189-6192
2. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R., and Futreal, P. A. (2002) Mutations of the BRAF gene in human cancer Nature 417, 949-954 (Pubitemid 34716871)
3. Dong, J., Phelps, R. G., Qiao, R., Yao, S., Benard, O., Ronai, Z., and Aaronson, S. A. (2003) BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma Cancer Res. 63, 3883-3885 (Pubitemid 36917898)
4. Dowell, J., Minna, J. D., and Kirkpatrick, P. (2005) Erlotinib hydrochloride Nature Rev. Drug Discovery 4, 13-14 (Pubitemid 40109581)
5. Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., Campos, D., Lim, R., Ding, K., Clark, G., Voskoglou-Nomikos, T., Ptasynski, M., and Parulekar, W. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol. 25, 1960-1966 (Pubitemid 46972777)
6. Tang, P. A., Tsao, M. S., and Moore, M. J. (2006) A review of erlotinib and its clinical use Expert Opin. Pharmacother. 7, 177-193 (Pubitemid 43263257)
7. Kalgutkar, A. S., Gardner, I., Obach, R. S., Shaffer, C. L., Callegari, E., Henne, K. R., Mutlib, A. E., Dalvie, D. K., Lee, J. S., Nakai, Y., O'Donnell, J. P., Boer, J., and Harriman, S. P. (2005) A comprehensive listing of bioactivation pathways of organic functional groups Curr. Drug Metab. 6, 161-225 (Pubitemid 40753853)
8. Ling, J., Johnson, K. A., Miao, Z., Rakhit, A., Pantze, M. P., Hamilton, M., Lum, B. L., and Prakash, C. (2006) Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers Drug Metab. Dispos. 34, 420-426 (Pubitemid 43290900)
9. Fan, P. W., Gu, C., Marsh, S. A., and Stevens, J. C. (2003) Mechanism-based inactivation of cytochrome P450 2B6 by a novel terminal acetylene inhibitor Drug Metab. Dispos. 31, 28-36 (Pubitemid 36735255)
10. Oswald, A. A., Griesbaum, K., Hudson, B. E., and Bregman, J. M. (1964) Organic sulfur compounds. XIII.1 Free-radical addition of thiols to phenylacetylene2 J. Am. Chem. Soc. 86, 2877-2884
11. Ortiz de Montellano, P. R. and De Voss, J. (2005) Substrate Oxidation by Cytochrome P450 Enzymes, in Cytochrome P450: Structure, Mechanism and Biochemistry (Ortiz de Montellano, P. R., Ed.) pp 183 - 245, Kluwer Academic/Plenum Publishers, Norwell, MA.
12. Testa, B. (1995) Monooxygenase-Catalyzed Oxidation of Oxygen and Sulfur-Containing Compounds, in Biochemistry of Redox Reactions (Testa, B. and Caldwell, J., Eds.) pp 235 - 283, Elsevier, New York.
13. Testa, B. (1995) Reactions Catalyzed by Peroxidases, in Biochemistry of Redox Reactions (Testa, B. and Caldwell, J., Eds.) pp 347 - 388, Elsevier, New York.
14. Hovorka, S. W. and Schöneich, C. (2001) Oxidative degradation of pharmaceuticals: Theory, mechanisms and inhibition J. Pharm. Sci. 90, 253-269 (Pubitemid 32209888)
15. Cole, L. M., Sanders, M., Palmer, C. J., and Casida, J. E. (1991) Structure-biodegradability relationships of insecticidal 1,4-disubstituted-2,6, 7-trioxabicyclo[2.2.2]octanes J. Agric. Food Chem. 39, 560-565
16. Ortiz de Montellano, P. R. and Grab, L. A. (1986) Cooxidation of styrene by horseradish peroxidase and glutathione Mol. Pharmacol. 30, 666-669 (Pubitemid 17228914)